Overview

Timolol for the Prevention of Proliferation of Infantile Hemangioma (TiPPIH Trial)

Status:
Terminated
Trial end date:
2016-04-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this trial is to see if a topical beta blocker is effective in preventing the proliferation of infantile hemangioma.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Alice K. Gong
Treatments:
Maleic acid
Timolol
Criteria
Inclusion Criteria:

- Babies admitted to NICU or seen in follow clinic that have a diagnosis of hemangioma
that is verified by Principal Investigator (PI) or Co-Principal Investigators.

Exclusion Criteria:

- Babies with PHACES (Posterior fossa, Hemangioma, Arterial lesions, Cardiac
abnormalities, Eye abnormalities) syndrome

- Babies with cardiac conditions that may predispose to heart block

- Babies with persistent hypoglycemia

- Babies on medications that may interact with beta blockers

- Babies who are hemodynamically unstable and are requiring pressors to maintain blood
pressure

- Babies who are on systemic corticosteroid therapy